HRP20151200T1 - Metoda za snižavanje intraokularnog tlaka kod ljudi - Google Patents

Metoda za snižavanje intraokularnog tlaka kod ljudi Download PDF

Info

Publication number
HRP20151200T1
HRP20151200T1 HRP20151200TT HRP20151200T HRP20151200T1 HR P20151200 T1 HRP20151200 T1 HR P20151200T1 HR P20151200T T HRP20151200T T HR P20151200TT HR P20151200 T HRP20151200 T HR P20151200T HR P20151200 T1 HRP20151200 T1 HR P20151200T1
Authority
HR
Croatia
Prior art keywords
substance
use according
pharmaceutical composition
glaucoma
iop
Prior art date
Application number
HRP20151200TT
Other languages
English (en)
Croatian (hr)
Inventor
Shikha Barman
Rudolf A. Baumgartner
Original Assignee
Inotek Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotek Pharmaceuticals Corporation filed Critical Inotek Pharmaceuticals Corporation
Publication of HRP20151200T1 publication Critical patent/HRP20151200T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
HRP20151200TT 2009-05-01 2010-04-30 Metoda za snižavanje intraokularnog tlaka kod ljudi HRP20151200T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17465509P 2009-05-01 2009-05-01
US21999009P 2009-06-24 2009-06-24
EP10770402.5A EP2424546B1 (en) 2009-05-01 2010-04-30 Method of reducing intraocular pressure in humans
PCT/US2010/033112 WO2010127210A1 (en) 2009-05-01 2010-04-30 Method of reducing intraocular pressure in humans

Publications (1)

Publication Number Publication Date
HRP20151200T1 true HRP20151200T1 (hr) 2016-01-15

Family

ID=43030847

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151200TT HRP20151200T1 (hr) 2009-05-01 2010-04-30 Metoda za snižavanje intraokularnog tlaka kod ljudi

Country Status (25)

Country Link
US (2) US8470800B2 (enExample)
EP (1) EP2424546B1 (enExample)
JP (1) JP5778663B2 (enExample)
KR (1) KR101757940B1 (enExample)
CN (1) CN102413832B (enExample)
AU (1) AU2010242943B2 (enExample)
BR (1) BRPI1009971A2 (enExample)
CA (1) CA2762064A1 (enExample)
CL (1) CL2011002675A1 (enExample)
DK (1) DK2424546T3 (enExample)
EA (1) EA024042B1 (enExample)
ES (1) ES2554684T3 (enExample)
HR (1) HRP20151200T1 (enExample)
HU (1) HUE028068T2 (enExample)
IL (1) IL216081A (enExample)
MX (1) MX2011011229A (enExample)
MY (1) MY159244A (enExample)
NZ (1) NZ596428A (enExample)
PL (1) PL2424546T3 (enExample)
PT (1) PT2424546E (enExample)
RS (1) RS54378B1 (enExample)
SG (1) SG175346A1 (enExample)
SI (1) SI2424546T1 (enExample)
SM (1) SMT201500295B (enExample)
WO (1) WO2010127210A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
KR20120091049A (ko) * 2009-10-26 2012-08-17 이노텍 파마슈티컬스 코포레이션 안과용 제제 및 이의 제조 방법
JP2013516495A (ja) * 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
CN102933220A (zh) * 2010-03-19 2013-02-13 伊诺泰克制药公司 用于降低眼内压的腺苷a1激动剂与碳酸酐酶抑制剂的组合型组合物
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
SMT201700377T1 (it) * 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
KR20170123605A (ko) * 2014-12-03 2017-11-08 이노텍 파마슈티컬스 코포레이션 황반 변성의 예방, 완화 또는 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01072B (me) 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
KR20120091049A (ko) * 2009-10-26 2012-08-17 이노텍 파마슈티컬스 코포레이션 안과용 제제 및 이의 제조 방법
JP2013516495A (ja) * 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
CN102933220A (zh) * 2010-03-19 2013-02-13 伊诺泰克制药公司 用于降低眼内压的腺苷a1激动剂与碳酸酐酶抑制剂的组合型组合物
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular

Also Published As

Publication number Publication date
PT2424546E (pt) 2015-12-23
HK1167599A1 (en) 2012-12-07
EA024042B1 (ru) 2016-08-31
CN102413832A (zh) 2012-04-11
BRPI1009971A2 (pt) 2016-03-15
DK2424546T3 (en) 2015-12-14
SG175346A1 (en) 2011-11-28
MX2011011229A (es) 2011-11-18
IL216081A0 (en) 2012-01-31
JP5778663B2 (ja) 2015-09-16
ES2554684T3 (es) 2015-12-22
EP2424546A4 (en) 2013-01-23
JP2012525437A (ja) 2012-10-22
HUE028068T2 (en) 2016-11-28
CL2011002675A1 (es) 2012-06-01
SMT201500295B (it) 2016-01-08
CN102413832B (zh) 2015-11-25
WO2010127210A1 (en) 2010-11-04
SI2424546T1 (sl) 2016-02-29
US20100279970A1 (en) 2010-11-04
KR101757940B1 (ko) 2017-07-13
AU2010242943B2 (en) 2016-09-29
NZ596428A (en) 2014-03-28
EP2424546B1 (en) 2015-10-28
MY159244A (en) 2016-12-30
AU2010242943A1 (en) 2011-12-01
PL2424546T3 (pl) 2016-04-29
RS54378B1 (sr) 2016-04-28
IL216081A (en) 2015-11-30
EP2424546A1 (en) 2012-03-07
US8470800B2 (en) 2013-06-25
CA2762064A1 (en) 2010-11-04
EA201171339A1 (ru) 2012-05-30
US20130217643A1 (en) 2013-08-22
KR20120017026A (ko) 2012-02-27

Similar Documents

Publication Publication Date Title
US20250387325A1 (en) Fixed dose combination of brimonidine and timolol
AU2011282681B2 (en) Preservative free bimatoprost and timolol solutions
KR20100135748A (ko) 아쥬반트로서의 안과용 ｎｓａｉｄ
CA3026053A1 (en) Treatment of dry eye disease with parasympathetic and anti-sympathetic agents
Aptel et al. Intraocular pressure-lowering combination therapies with prostaglandin analogues
JP2022508715A5 (enExample)
CA3081593A1 (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
ME02608B (me) Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
JP2023168397A (ja) 眼科組成物
CA3073718A1 (en) Ocular pharmaceutical compositions
ME02594B (me) Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska
Simmons et al. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension
ES2764654T3 (es) Combinaciones de prostaglandinas y donantes de óxido nítrico
KR20230158076A (ko) 눈 질환을 치료하기 위한 방법 및 조성물
JP2012250951A (ja) アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤
TWI809021B (zh) 含有ＦＰ促效藥及β阻斷藥的青光眼治療劑
JPWO2006098292A1 (ja) 眼疾患治療剤
WO2013150277A1 (en) Ophthalmic therapy
JP2012250953A (ja) アデノシン誘導体とα２受容体作動薬の組合せ剤
JP2012250947A (ja) アデノシン誘導体とβ受容体遮断薬の組合せ剤
Srivastava et al. Recent updates on medical management of Glaucoma.
HK40109101A (en) A pharmaceutical composition for effectively delaying and treating myopia
JP2012250950A (ja) アデノシン誘導体とプロスタグランジン類の組合せ剤
WO2024240216A9 (zh) 一种有效延缓及治疗近视的药物组合物
JP2016034936A (ja) 角膜上皮障害治療剤の組み合わせ